HMBD-001

Phase 2Small molecule

HHummingbird Bioscience

HMBD-001 is one of 96 small molecule programs targeting Patients With Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Solid TumorsActive, not recruiting

Non-Small Cell Lung CancerRecruiting

Solid TumoursActive, not recruiting

Patients With Solid TumorsPhase 1

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Recruiting

Solid TumoursPhase 2

Active, not recruiting

Competition

Competitive Landscape

449 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Nano-Crystalline Megestrol Acetate

Changchun GeneScience Pharmaceutical Co., Ltd.

Phase 3

1 2

Anktiva

SSWOG Cancer Research Network

Phase 3

1 3

Carboplatin/paclitaxel

AstraZeneca

Phase 3

3 4

HMBD-001

HHummingbird Bioscience

Phase 2

1 5

Remeron

OOrganon and Co

Preclinical

1 6

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—7

Valemetostat Tosylate

Daiichi Sankyo

Preclinical

1 8

Vibramycin

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Treatment

1 10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Active, not recruiting

Patients With Solid Tumors

NCT05919537

Clinical

Trials by Indication[1]

Patients With Solid Tumors1 trial

Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation

Active, not recruiting·HHummingbird Bioscience·Phase 1·NCT05919537·68 enrolled

Solid Tumours1 trial

A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours

Active, not recruiting·CCancer Research UK·Phase 1/2·NCT05057013·81 enrolled

Non-Small Cell Lung Cancer1 trial

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

Recruiting·HHummingbird Bioscience·Phase 1/2·NCT05910827·98 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for HMBD-001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HMBD-001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HMBD-001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hummingbird Bioscience company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHummingbird Bioscience

HMBD-001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Patients With Solid Tumors1 trial

Solid Tumours1 trial

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News